Holen Sie sich die Stockscreener-App
1.46
4.29%
0.06
Handel nachbörslich:
1.44
-0.02
-1.37%
Schlusskurs vom Vortag:
$1.40
Offen:
$1.39
24-Stunden-Volumen:
4.75M
Relative Volume:
1.86
Marktkapitalisierung:
$1.10B
Einnahmen:
$581.12M
Nettoeinkommen (Verlust:
$-212.92M
KGV:
-5.3324
EPS:
-0.2738
Netto-Cashflow:
$-174.22M
1W Leistung:
+12.31%
1M Leistung:
+32.73%
6M Leistung:
+6.57%
1J Leistung:
+5.80%
1-Tages-Spanne:
$1.37
$1.465
1-Wochen-Bereich:
$1.29
$1.50
52-Wochen-Spanne:
$0.9769
$1.60
Opko Health Inc Stock (OPK) Company Profile
Firmenname
Opko Health Inc
Sektor
Branche
Telefon
305-575-4181
Adresse
4400 BISCAYNE BLVD., MIAMI, FL
Compare OPK vs TMO, DHR, IDXX, A, WAT
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OPK
Opko Health Inc
|
1.46 | 1.06B | 581.12M | -212.92M | -174.22M | -0.2738 |
TMO
Thermo Fisher Scientific Inc
|
473.95 | 179.15B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
178.08 | 124.65B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
560.73 | 43.45B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
137.40 | 38.14B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
379.77 | 36.52B | 3.77B | 449.25M | 240.68M | 7.8556 |
Opko Health Inc Stock (OPK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-20 | Eingeleitet | JP Morgan | Neutral |
| 2025-10-31 | Herabstufung | Jefferies | Buy → Hold |
| 2025-04-25 | Eingeleitet | JP Morgan | Neutral |
| 2023-06-29 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2022-12-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-01-24 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2021-06-21 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2019-11-25 | Eingeleitet | Piper Jaffray | Overweight |
| 2018-03-02 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2017-09-14 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2016-06-21 | Bestätigt | Standpoint Research | Buy |
| 2016-06-03 | Eingeleitet | Standpoint Research | Buy |
| 2016-03-31 | Bestätigt | Barrington Research | Outperform |
| 2015-10-16 | Eingeleitet | JP Morgan | Overweight |
| 2015-09-11 | Herabstufung | Jefferies | Buy → Hold |
| 2015-03-03 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2014-05-12 | Bestätigt | Oppenheimer | Outperform |
| 2014-03-14 | Eingeleitet | Oppenheimer | Outperform |
| 2013-11-13 | Bestätigt | Ladenburg Thalmann | Buy |
| 2013-05-30 | Bestätigt | Ladenburg Thalmann | Buy |
| 2012-10-22 | Eingeleitet | Barrington Research | Outperform |
| 2011-12-01 | Bestätigt | Ladenburg Thalmann | Buy |
| 2011-07-14 | Eingeleitet | Ladenburg Thalmann | Buy |
Alle ansehen
Opko Health Inc Aktie (OPK) Neueste Nachrichten
OPK Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
OPKO Health (OPK) up 17.1% since last earnings report: Can it continue? - MSN
Here's why you should retain OPK stock in your portfolio for now - MSN
OPKO Health Inc stock (US68375N1037): shares trade steady after recent earnings while valuation stay - AD HOC NEWS
OPKO Health (OPK) Up 17.1% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Here's Why You Should Retain OPK Stock in Your Portfolio for Now - Zacks Investment Research
OPKO Health stock (US68375N1037): earnings update keeps focus on pipeline and Rayaldee outlook - AD HOC NEWS
OPKO Health (OPK) price target increased by 11.18% to 3.86 - MSN
OPKO Health stock (US68375N1037): Company updates keep the biotech name in focus - AD HOC NEWS
Opko Health, Inc.Common Stock (NQ: OPK - FinancialContent
OPKO Health stock (US68375N1037): Genomics leader with recent subsidiary activity - AD HOC NEWS
ModeX to present preclinical CAR-T data at gene therapy meeting - Investing.com UK
OPKO Health’s ModeX Therapeutics Will Present Data - GlobeNewswire
Spotlight On Promising Penny Stocks For May 2026 - simplywall.st
OPK.O| Stock Price & Latest News - Reuters
Here's why you should hold OPK stock in your portfolio for now - msn.com
OPKO Health, Inc. (NASDAQ:OPK) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
MSN Money - MSN
OPK Stock Price, Quote & Chart | OPKO HEALTH INC (NASDAQ:OPK) - ChartMill
OPKO Health, Inc. (NASDAQ:OPK) Just Reported And Analysts Have Been Lifting Their Price Targets - 富途牛牛
HC Wainwright Boosts Earnings Estimates for OPKO Health - MarketBeat
OPKO Health : Notice Annual Meeting of stockholders be held on Thursday, June 18, 2026. - marketscreener.com
OPKO gains 15% stake in Nicoya for China RAYALDEE rights - Investing.com UK
[ARS] OPKO HEALTH, INC. SEC Filing - Stock Titan
Board structure and pay detailed in OPKO Health (NASDAQ: OPK) 2026 proxy - Stock Titan
OPKO gains 15% stake in Nicoya for China RAYALDEE rights By Investing.com - Investing.com South Africa
OPKO Health receives 15% stake in Nicoya for China drug rights - StreetInsider
OPKO Health Expands Nicoya Agreement to Support RAYALDEE® Commercialization in Greater China - marketscreener.com
Q1 Earnings Estimate for OPKO Health Issued By HC Wainwright - MarketBeat
Order lab tests online or at home: BioReference opens new platform - Stock Titan
BioReference Launches BioReference Direct, Expanding Access to Consumer-Initiated Diagnostic Testing Through a Fully Integrated Digital Platform - Moomoo
OPKO Health (OPK) reports Q1 loss, misses revenue estimates - MSN
OPKO Health Q1 Earnings In-Line on Product Gains, Revenues Down Y/Y - sharewise.com
OPKO Health Down Over 13%, On Pace for Largest Percent Decrease Since January 2024 -- Data Talk - Moomoo
OPKO Health (NASDAQ:OPK) Hits New 1-Year LowShould You Sell? - MarketBeat
This Purple Innovation Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga
H.C. Wainwright reiterates Opko Health stock rating on Q1 results By Investing.com - Investing.com Australia
OPKO Health (NASDAQ:OPK) Downgraded to "Market Perform" Rating by Barrington Research - MarketBeat
H.C. Wainwright reiterates Opko Health stock rating on Q1 results - Investing.com
OPKO Health Q1 2026 Earnings Call: Complete Transcript - Benzinga
Finanzdaten der Opko Health Inc-Aktie (OPK)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.26%
0.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):